Biothera Further Elucidates The Mechanism Of Action Of Cancer Immunotherapy Imprime PGG

Published: Jan 30, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EAGAN, Minn.--(BUSINESS WIRE)--Imprime PGG®, the phase 3 cancer immunotherapy drug from Biothera, utilizes distinct receptors and signaling pathways in monocytes to induce cytotoxic function. The research was published in the latest issue of Glycobiology.

Help employers find you! Check out all the jobs and post your resume.

Back to news